A male patient on testosterone therapy reports flushing; what is the likely cause and how should it be evaluated and managed?

Flushing in Men on Testosterone Therapy

Flushing in a man taking testosterone is most likely related to supraphysiologic testosterone levels or erythrocytosis, and you should immediately check his serum testosterone level (midway between injections if using injectable formulations) and hematocrit to guide dose adjustment.

Likely Causes and Pathophysiology

The flushing is most commonly caused by:

1. Supraphysiologic Testosterone Levels

Excessive testosterone dosing leads to elevated bioavailable testosterone and estradiol (via aromatization), which can trigger vasomotor symptoms including flushing 1. This is particularly common with:

• Injectable testosterone esters (enanthate, cypionate) - highest risk
• Testosterone gels at higher doses (100 mg/day delivering 10 mg/day)
• Any formulation when dosed too frequently or at excessive amounts

2. Erythrocytosis-Related Hyperviscosity

Testosterone therapy commonly causes dose-dependent increases in hematocrit 2, 1. Erythrocytosis occurs in:

• 43.8% of patients on intramuscular injections
• 17.9% on high-dose gels (100 mg/day)
• 15.4% on transdermal patches
• Only 2.8% on low-dose preparations (5 mg/day)

The increased blood viscosity can cause flushing, particularly facial flushing 2.

3. Rare: Pseudocarcinoid Syndrome

In men with secondary hypogonadism specifically, flushing with elevated urinary 5-HIAA can occur, which paradoxically resolves with testosterone treatment 3. This is the opposite scenario - flushing from testosterone deficiency rather than excess.

Immediate Evaluation Algorithm

Step 1: Check Testosterone Level (Timing Matters)

• Injectable testosterone (enanthate/cypionate): Measure midway between injections. Target 400-700 ng/dL 1, 4
  • If >700 ng/dL: Reduce dose or increase injection interval
  • If >600 ng/dL with symptoms: Still consider dose reduction 4
• Transdermal gel: Measure 2-8 hours after application 4
• Patches: Measure 3-12 hours after application 1

Step 2: Check Hematocrit Immediately

• If hematocrit >54%: Stop testosterone therapy immediately until it decreases to safe levels 1, 5, 1, 4
• Evaluate for hypoxia and sleep apnea (which worsen erythrocytosis)
• Reinitiate at reduced dose once hematocrit normalizes
• Consider therapeutic phlebotomy if needed 2

Step 3: Assess Formulation-Specific Issues Per Endocrine Society guidelines 1, evaluate:

• Injectable esters: Ask specifically about mood/libido fluctuations and flushing episodes
• Patches: Examine for local skin reactions
• Gels: Assess application technique and coverage

Management Strategy

If Testosterone Level is Elevated (>700 ng/dL):

1. Reduce dose immediately:

   • Injectable: Decrease dose by 25-50% OR increase injection interval
   • Gel: Step down to lower dose formulation
   • Patches: Use fewer patches or lower-dose patch

2. Recheck in 3-6 months with appropriately timed level 1, 4

If Hematocrit is >54%:

1. Hold testosterone completely 1, 5, 1, 4
2. Evaluate for secondary causes:
   • Sleep apnea screening (especially if obese, snoring, daytime somnolence)
   • Pulse oximetry for hypoxia
   • Consider COPD if smoking history
3. Restart at 50% dose once hematocrit <50%
4. Monitor hematocrit every 3 months until stable 4

If Both Testosterone and Hematocrit are Normal:

Consider alternative causes of flushing 6, 7:

• Carcinoid syndrome (check 24-hour urinary 5-HIAA, serum chromogranin A)
• Pheochromocytoma (check plasma metanephrines)
• Mastocytosis (check serum tryptase)
• Medications (calcium channel blockers, niacin, alcohol)

Critical Pitfalls to Avoid

1. Wrong timing of testosterone measurement: Measuring at peak (immediately after injection) or trough (just before next injection) gives misleading values. Always measure midway for injectables 1, 5, 1, 4.

2. Ignoring hematocrit >54%: This threshold is absolute per all major guidelines 1, 5, 1, 4. Continuing therapy risks thromboembolism, though no cases have been definitively reported to date 2.

3. Assuming flushing is benign: While often related to dosing, flushing can signal serious conditions. The systematic evaluation cannot be skipped 6, 7.

4. Injectable formulations carry highest risk: If flushing persists despite dose adjustment, consider switching from injectable to transdermal formulations, which have lower rates of both supraphysiologic levels and erythrocytosis 2.

Monitoring Going Forward

Once flushing resolves with dose adjustment 1, 4:

• Testosterone level at 3-6 months, then annually
• Hematocrit at 3-6 months, then annually
• Target testosterone: 450-600 ng/dL (mid-normal range) 4, 8
• Target hematocrit: <54% (ideally <50%)

The key principle: Flushing on testosterone therapy is a red flag for overdosing or erythrocytosis until proven otherwise, and both require immediate dose reduction or therapy cessation.